EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Ayu Kiritani, Yoshiaki Amino iD, Ken Uchibori iD, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu iD, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio iD

Thoracic Cancer · 2024-02 · 15 (5) · 402-409

DOI: 10.1111/1759-7714.15210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 16.01.2024. Verfasst von Ayu Kiritani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Jikei University School of Medicine, Minato, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant, Acrylamides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR ‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudied. This study aimed to evaluate the impact of osimertinib on time to treatment failure (TTF) and overall survival (OS) in patients with EGFR ‐mutation positive NSCLC, comparing those with and without MPE.

Methods

This retrospective analysis included patients with advanced or recurrent NSCLC treated with osimertinib at our hospital between April 2016 and June 2021. TTF was defined as the duration from osimertinib initiation to discontinuation, and OS as the duration until death, irrespective of the reason.

Results

Among 229 patients receiving osimertinib, 84 had MPE before administration, 39 acquired EGFR exon20 T790M mutation following previous EGFR‐TKI therapy, and 45 were EGFR‐TKI‐naive. Among EGFR‐TKI‐naive patients, median TTF was 14.8 and 19.8 months for those with and without MPE, respectively (hazard ratio [HR] 1.40; 95% confidence interval [CI]: 0.90–2.18; p = 0.12). Median OS was 32.0 and 42.0 months for patients with and without MPE, respectively (HR 1.43; 95% CI: 0.86–2.38; p = 0.16). Among patients with T790M mutation, median TTF was 12.3 and 13.1 months for patients with and without MPE, respectively (HR 1.03; 95% CI: 0.69–1.55; p = 0.88). Median OS for patients with and without MPE was 23.2 and 24.7 months, respectively (HR 1.09; 95% CI: 0.72–1.67; p = 0.68).

Conclusion

Among patients with EGFR ‐mutation positive NSCLC, the evidence of MPE has little effect on survival with osimertinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPleural Effusion, MalignantAcrylamidesAniline CompoundsIndolesPyrimidinesHumansErbB ReceptorsRetrospective StudiesProtein Kinase InhibitorsMutationNeoplasm Recurrence, Local

Stichwörter der Autor:innen

EGFRmalignant pleural effusionnon-small cell lung cancerosimertinib

Substanzen

osimertinibErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Jikei University School of Medicine, Minato, Japan.
  • Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Japan.
  • Department of Respiratory Medicine, Hachinohe City Hospital, Hachinohe, Japan.
  • Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
  • Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Division of Allergology and Respiratory Medicine, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Japan.

ORCID-Profile: Yoshiaki Amino, Ken Uchibori, Ryo Ariyasu, Makoto Nishio

Zitieren

APA

Kiritani, A., Amino, Y., Uchibori, K., Akita, T., Harutani, Y., Ogusu, S., Tsugitomi, R., Manabe, R., Ariyasu, R., Kitazono, S., Yanagitani, N., & Nishio, M. (2024). Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion. Thoracic Cancer, 15(5), 402-409. https://doi.org/10.1111/1759-7714.15210

Vancouver

Kiritani A, Amino Y, Uchibori K, Akita T, Harutani Y, Ogusu S, et al. Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion. Thoracic Cancer. 2024;15(5):402-409. doi:10.1111/1759-7714.15210

BibTeX
@article{Kiritani2024,
  author = {Kiritani, Ayu and Amino, Yoshiaki and Uchibori, Ken and Akita, Takahiro and Harutani, Yuhei and Ogusu, Shinsuke and Tsugitomi, Ryosuke and Manabe, Ryo and Ariyasu, Ryo and Kitazono, Satoru and Yanagitani, Noriko and Nishio, Makoto},
  title = {Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {5},
  pages = {402--409},
  doi = {10.1111/1759-7714.15210}
}
Kostenlos starten →